William Schelman, MD

Trials

Studies that name William Schelman, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:55 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT06291415 · The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

  Hutchmed · withdrawn · Immune Thrombocytopenia, Blood Platelet Disorder, Hematologic Diseases · study director
• Ph1/Ph2
  NCT05077384 · Open-label Study of Surufatinib in Japanese Patients

  Hutchmed · completed · Neuroendocrine Tumors, Non-hematologic Malignancy · study director
• Ph2
  NCT04579679 · Open-Label Surufatinib in European Patients With NET

  Hutchmed · terminated · Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET · study director
• Ph1/Ph2
  NCT04577963 · A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

  Hutchmed · terminated · Triple Negative Breast Cancer, Endometrial Cancer, Solid Tumor, Unspecified, Adult · study director
• Ph1/Ph2
  NCT04579757 · Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

  Hutchmed · terminated · Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors · study chair
• Ph3
  NCT04322539 · A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer

  Hutchison Medipharma Limited · completed · Metastatic Colorectal Cancer, Metastatic Colon Cancer · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 01:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.